Cellex Symposium 2026 Celebrates 25 Years of Advancements in Cell and Gene Therapy

Cellex Symposium 2026: A Landmark Event in Cell and Gene Therapy



On November 8, 2026, more than 100 researchers, clinicians, and industry experts convened at the Wasserturm Hotel in Cologne for the Cellex Symposium 2026. The theme, "Cell and Gene Therapy at a Turning Point," marked not only a significant gathering of thought leaders but also celebrated the 25th anniversary of Cellex Cell Professionals, a company that has evolved from a service provider in apheresis to a leading organization in the field of cell therapy and contract development and manufacturing.

The symposium featured ten scientific presentations across three dedicated sessions, focusing on the entire trajectory of cell and gene therapies from research and development to global commercialization. The event commenced with an opening session titled "Translation From Cells to Clinical Impact," aimed at discussing the clinical implementation of cell therapies. Notable contributors included Dr. Hyatt Balke-Want from the University Hospital of Cologne, Jens Altrichter from Artcline GmbH, and Matthias Domogalla from Cellex. They elaborated on topics such as genetically modified T cells, allogeneic immunotherapy in sepsis treatment, and compliance with good manufacturing practices (GMP) as a key determinant of manufacturing performance.

The second session, "Targeting," turned the spotlight on challenging cancers and genetic disorders, featuring discussions around peptide vaccines, gene editing platforms, and TCR-directed T cells with a focus on PRAME and difficult-to-target antigens within solid tumors and hematologic malignancies. Esteemed presenters included Professor Elke Jäger from North-West Hospital Frankfurt, Professor Frank Buchholz from Technical University Dresden, and Dr. Ali Mohammed from Immatics Biotechnologies.

During the symposium, experts engaged in roundtable discussions on the role of artificial intelligence within a regulated environment, contemplating how to maintain product quality across various production sites. The closing session, titled "Market Reality," addressed scaling up production by focusing on GMP raw materials, integrated CDMO models, and the role of China in the global biotechnology landscape. Key insights were provided by Rachel Atlee of Akron Bio, Dr. Suvi Annala of Cellex, and Ping Shek of STBio Limited.

The symposium provided an excellent opportunity for attendees to reconnect with friends and collaborators in the cell and gene therapy sector. Professor Martin Wermke, Director of the Early Clinical Trials Unit at the National Center for Tumor Diseases in Dresden, emphasized the importance of the event stating, "In just one day, the symposium covered the entire journey from research and development to commercialization. The open exchange between academia and industry clearly demonstrated that the decisions made today will shape the next decade in our field."

Dr. Armin Ehninger, Chief Scientific Officer and Strategist at Cellex, remarked, "Advanced therapies can only be accessed by patients on a large scale if science, manufacturing, and regulatory expertise advance in concert. This symposium successfully gathered these perspectives in one room, and we are excited to continue these exchanges with our partners."

Founded 25 years ago to support stem cell donor registries through apheresis services, Cellex Cell Professionals has now become a CDMO specializing in cell therapy, with over a decade of experience in manufacturing autologous and allogeneic products. The company aids pharmaceutical, biotech, and academic partners throughout preclinical and clinical development phases, as well as commercial production. By integrating GMP-compliant manufacturing expertise with a collection of cell raw materials and supply chain capabilities, Cellex stands at the forefront of the industry.

For more information about Cellex and their ongoing innovations, please visit www.cellex.me/en.

Press Contact


Elena Görris
Strategic Marketing Manager
Cellex Cell Professionals GmbH
Email: [email protected]
Phone: +49 151 12410817

Join us as we continue to shape the future of cell and gene therapy together.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.